22 Oct

Hub and spoke IP strategies are generating billions of dollars in biopharma

The creation of Radionetics Oncology is just latest sign in recent months of the growth of hub-and-spoke businesses which promise to disrupt IP monetisation in the life sciences

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth